Table 1.
Demographic and clinical characteristics of study participants
| Measles-seropositive* at 1 year post- revaccination (n = 10) | Measles-seronegative* at 1 year post- revaccination (n = 9) | ||
|---|---|---|---|
| Enrolment | Mean (range) or n (%) | Mean (range) or n (%) | P-value (χ2 or t-test) |
| Age | 9·7 (3·3–11·9) | 7·7 (4·2–11·5) | 0·0769 |
| Male | 8 (80%) | 6 (67%) | 0·4343 |
| CD4% | 33 (18–60) | 29 (15-50) | 0·8132 |
| HIV viral load† | 41 473 (0–155 430) | 22 753 (0–226 820) | 0·5575 |
| Time on ART (years) | 3·8 (0·2–7·0) | 3·2 (1·3–6·0) | 0·5709 |
| Measles antibody titre (log10 mIU/ml) | Seronegative | Seronegative | n.a. |
| 1 month post-revaccination | |||
| CD4% | 43·7 (35·3–46·0) | 41·3 (26·7–49·9) | 0·6546 |
| Measles antibody titre (log10 mIU/ml) | 3·4 (2·8–3·8) | 3·0 (2·6–3·5) | 0·0057 |
| 1 year post-revaccination | |||
| CD4% | 32 (16–55) | 30 (15–47) | 0·4675 |
| HIV viral load | 1721 (0–15 302) | 16 096 (0–49 509) | 0·0813 |
| HIV virological failure‡ | 1 (10%) | 3 (33%) | 0·2130 |
| Measles antibody titre (log10 mIU/ml) | 3·0 (2·6–4·0) | Seronegative | n.a. |
*
Measles-seropositive refers to a measles-specific immunoglobulin (Ig)G antibody titre ≥ 350 mIU/ml of serum. †Copies of HIV per ml of blood.
†
Two consecutive HIV viral load measurements greater than 1000 copies per ml of blood.
ART = anti-retroviral therapy; n.a. = not available.